Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Could a simple drug replace knee surgery? Stanford researchers found that blocking an age-related protein called 15-PGDH can regrow damaged knee cartilage in old mice and even in human tissue from knee replacement patients. The discovery could pave the way for an oral drug or injection that treats osteoarthritis at its root — no surgery required.
Stanford scientists may have found a way to actually reverse cartilage loss — not just manage the pain. By blocking a protein called 15-PGDH, which naturally increases with age, researchers were able to regrow hyaline cartilage (the smooth, joint-cushioning kind) in older mice. The treatment also dramatically reduced the risk of osteoarthritis developing after ACL-like knee injuries — a condition that currently affects about 50% of people within 15 years of such an injury.
What makes this especially notable is the human angle: cartilage samples taken from knee replacement patients began regenerating functional articular cartilage after just one week of exposure to the 15-PGDH inhibitor. And unlike previous theories, the regeneration didn't rely on stem cells — existing cartilage cells simply shifted back toward a younger, healthier state.
Key Takeaways:
Why it matters: Osteoarthritis affects 1 in 5 U.S. adults and costs ~$65 billion annually in direct healthcare costs, with no disease-modifying drugs currently available. A treatment that regenerates cartilage could transform care for millions and significantly reduce the burden of joint replacement surgeries.
